FreeStyle Libre is a factory-calibrated continuous 14-day glucose sensor. Little is known about the accuracy of FreeStyle Libre as a function of sensor age. We assessed the accuracy of FreeStyle Libre in 14 adults with type 1 diabetes. Each study participant attended our research facility for two or three 24-h visits, during which they wore a FreeStyle Libre aged 0-1 day, 5-7 days, or 13-14 days. Plasma glucose levels were measured every 10-30 min using YSI2300 STAT Plus Analyser. Participants also wore Dexcom G5 glucose sensor aged 1-2 days. We assessed sensors' accuracy using mean absolute relative difference (MARD) between FreeStyle Libre, the Dexcom G5 sensor, and plasma glucose. We had 1930 pairs of FreeStyle Libre sensor-plasma glucose measurements, collected from 36 FreeStyle Libre sensors, 18 of which were sensors aged 0-1 day, 9 were sensors aged 5-7 days, and 9 were sensors aged 13-14 days. The mean and median MARD for FreeStyle Libre sensors aged 0-1 days were 14.5% and 11.2%, respectively, and for sensors aged 13-14 days were 14.7% and 11.2%, respectively, but for sensors aged 5-7 days were 7.8% and 6.6%, respectively ( = 0.03 vs. sensors aged 0-1 days, and  = 0.06 vs. sensors aged 13-14 days). The percentage of points falling in the potentially dangerous zones C, D, or E in Clarke's error grid analysis were 1.9% for FreeStyle Libre sensors aged 0-1 day, 0.2% for sensors aged 5-7 days, and 0.4% for sensors aged 13-14 days. The overall accuracy of FreeStyle Libre and Dexcom G5 sensor was the same (mean MARD 12.8% and 12.5%, respectively;  = 0.57). FreeStyle Libre's accuracy is adequate during its entire lifetime but is least accurate during its first and last days. ClinicalTrials.gov Identifier: NCT02814123.

Download full-text PDF

Source
http://dx.doi.org/10.1089/dia.2019.0262DOI Listing

Publication Analysis

Top Keywords

freestyle libre
44
sensors aged
44
aged 0-1
20
13-14 days
20
accuracy freestyle
16
5-7 days
16
aged 13-14
16
aged
13
days
13
0-1 day
12

Similar Publications

Background: Continuous glucose monitors (CGMs) are used to characterize postprandial glucose responses and provide personalized dietary advice to minimize glucose excursions. The efficacy of such advice depends on reliable glucose responses.

Objectives: To explore within-subject variability of CGM responses to duplicate presented meals in an inpatient setting.

View Article and Find Full Text PDF

Continuous glucose monitoring (CGM) has emerged as a superior method to glycated hemoglobin (HbA1c) monitoring for glycemic control assessment in type 1 diabetes (T1D). The association between CGM parameters and diabetic kidney disease (DKD) has not been extensively researched. The aim of the present study was to compare CGM metrics between patients with stable and progressive DKD and T1D.

View Article and Find Full Text PDF

Background: People with diabetes benefit from continuous glucose monitoring (CGM) systems. A downside of these valuable aids for diabetes management is the generation of a tremendous amount of waste. This study aimed to quantify this CGM-related waste.

View Article and Find Full Text PDF

Objective: To assess the accuracy of a flash glucose monitoring system (FGMS; FreeStyle Libre 2) in healthy dogs during isoflurane general anesthesia.

Methods: 6 purpose-bred Beagle dogs underwent 3 anesthetic events, 1 week apart, in a randomized crossover study. 1 of 3 mean arterial blood pressure (MAP) states were induced under isoflurane anesthesia (hypotension [MAP, ≤ 60 mm Hg], normotension [MAP, 80 to 120 mm Hg], and hypertension [MAP, ≥ 120 mm Hg]) for 40 minutes.

View Article and Find Full Text PDF

Objective: The benefits of continuous glucose monitoring (CGM) in managing hyperglycemia in hospitalized patients with type 2 diabetes (T2D) have been documented in observation and intervention clinical studies. However, the benefits of CGMs after hospital discharge in improving the care of patients with T2D remain unknown.

Methods: This pilot randomized clinical trial aimed to compare the effectiveness and safety of using the FreeStyle Libre 2 CGM versus capillary point-of-care (POC) glucose testing (standard of care) in insulin-treated patients with T2D for up to 12 weeks after hospital discharge.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!